[
  {
    "ts": null,
    "headline": "Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology",
    "summary": "Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi, showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. Cenerimod was shown to be well tol",
    "url": "https://finnhub.io/api/news?id=821d8dc16c963f2e37e67e11a6cb07928017665ec971c068881979b77b31649e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734523140,
      "headline": "Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology",
      "id": 132046086,
      "image": "https://media.zenfs.com/en/prnewswire.com/4224d4f6c629cb47fa612cf0b1e68340",
      "related": "VTRS",
      "source": "Yahoo",
      "summary": "Viatris Inc. (NASDAQ: VTRS) today announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The results, published in Lancet Rheumatologyi, showed cenerimod 4 mg demonstrated clinically meaningful and sustained improvement from baseline on multiple measures of SLE disease activity compared to placebo, in addition to stable background SLE therapy. Cenerimod was shown to be well tol",
      "url": "https://finnhub.io/api/news?id=821d8dc16c963f2e37e67e11a6cb07928017665ec971c068881979b77b31649e"
    }
  }
]